OncoMatch/Clinical Trials/NCT06709859
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Is NCT06709859 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Afatinib plus chemotherapy as conversion treatment for carcinoma, non-small-cell lung.
Treatment: Afatinib plus chemotherapy as conversion treatment — This is a phase II, single-arm study to evaluate the efficacy and safety of Afatinib plus chemotherapy as conversion treatment in patients with unresectable EGFR sensitive mutation-positive stage III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitive mutation
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Prior systemic anti-cancer therapy for non-small cell lung cancer
Cannot have received: local radiotherapy
Prior local radiotherapy for NSCLC
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify